A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

Secondary Central Nervous System Lymphoma Clinical Trial

Official title:
A Phase II, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Recurrent/Refractory Central Nervous System Lymphoma and Recurrent/Refractory Secondary Central Nervous System Lymphoma

Status Active, not recruiting

Clinical Trial Summary

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

Clinical Trial Description

Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with Recurrent/Refractory Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) will be evaluated in approximately 82 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects . ;

Study Design

Related Conditions & MeSH terms

Lymphoma
Neoplasm Metastasis
PCNSL
Secondary Central Nervous System Lymphoma

Clinical Trial Details

NCT number	NCT04438044
Study type	Interventional
Source	Beijing InnoCare Pharma Tech Co., Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 18, 2019
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04457869` - A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)	Phase 2
Recruiting	`NCT05351593` - Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03964090` - Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)	Phase 2
Recruiting	`NCT05011045` - Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Recruiting	`NCT05256641` - Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05398224` - R-MTX-zanbrutinib in Secondary CNS Lymphoma	Phase 2
Recruiting	`NCT05485753` - A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)	Phase 1/Phase 2
Recruiting	`NCT05681195` - Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas	Phase 2